|Bid||208.68 x 4000|
|Ask||209.07 x 900|
|Day's Range||207.08 - 214.48|
|52 Week Range||132.75 - 216.47|
|Beta (3Y Monthly)||1.55|
|PE Ratio (TTM)||66.68|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||1.28 (0.65%)|
|1y Target Est||210.71|
MINNEAPOLIS , June 17, 2019 /PRNewswire/ -- Bio-Techne today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its ExoDx Prostate IntelliScore (EPI) ...
MINNEAPOLIS, June 13, 2019 /PRNewswire/ -- Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate IntelliScore (EPI) test in New York, providing a valuable tool to help Urologists rule out unnecessary prostate biopsies. The EPI test was launched in the U.S. in 2017. With this approval, the EPI test is now available to Urologists in New York State.
Bio-Techne Corp NASDAQ/NGS:TECHView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for TECH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting TECH. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $894 million over the last one-month into ETFs that hold TECH are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.
MINNEAPOLIS, June 4, 2019 /PRNewswire/ -- Bio-Techne Corporation (TECH) announced today it has reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc. The transaction has been completed and is being financed through available cash on hand. "We are very pleased to include the B-MoGen technology in Bio-Techne's expanding portfolio of products that serve the rapidly growing cell and gene therapy markets," commented Charles R. Kummeth, President and Chief Executive Officer of Bio-Techne. "B-MoGen's technologies solve the most complex gene editing problems with proprietary, cutting edge gene editing and delivery tools, enabling and accelerating growth in immunotherapy treatments.
here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank 2 (Buy) or better.
MINNEAPOLIS , June 3, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Goldman Sachs 40 th Annual ...
MINNEAPOLIS, May 28, 2019 /PRNewswire/ -- Bio-Techne today announced the publication of a recent validation study demonstrating that the proprietary exosome-based liquid biopsy tests from Bio-Techne's Exosome Diagnostics brand may be used to assess the mutational status of the Epidermal Growth Factor Receptor (EGFR) gene in patients with non-small cell lung cancer (NSCLC). The data from this study will be available to discuss at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4 in Chicago, IL. NSCLC is the most common type of lung cancer.
MINNEAPOLIS , May 21, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
MINNEAPOLIS , May 14, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the UBS Global Healthcare Conference ...
New Roche detection kits, combined with Bio-Techne's ACD RNAscope® reagent kits, increase singleplex and multiplex testing capabilities on automated platform INDIANAPOLIS , May 6, 2019 /PRNewswire/ -- ...
MINNEAPOLIS , May 2, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel , Chief Financial Officer will present at the Bank of America Merrill Lynch 2019 Health Care ...
MINNEAPOLIS , April 30, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2019 . Third Quarter FY2019 Snapshot Third quarter ...
MINNEAPOLIS , April 30, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, ...
Charles Kummeth has led Minneapolis-based Bio-Techne Corp. through 14 acquisitions that have transformed the once-quiet firm into a far-reaching enterprise.
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]